Design and development of BACE-1 inhibitors.
Curr Opin Drug Discov Devel
; 7(4): 536-56, 2004 Jul.
Article
in En
| MEDLINE
| ID: mdl-15338962
ABSTRACT
In early 1999, beta-amyloid cleaving enzyme-1 (BACE-1) was identified as the protease responsible for the critical first step in the processing of beta-amyloid precursor protein that ultimately leads to the production of Abeta peptides in the brain. Accumulation of these peptides has been implicated in the pathology of Alzheimer's disease (AD). An inhibitor of BACE-1 would therefore have therapeutic potential to slow or halt the progression of this debilitating and ultimately fatal disease. This review provides a perspective on the recent developments in the design of BACE-1 inhibitors. An overview of early research is also included, with particular emphasis on a comprehensive survey of the patent literature.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Drug Design
/
Aspartic Acid Endopeptidases
Limits:
Humans
Language:
En
Journal:
Curr Opin Drug Discov Devel
Journal subject:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Year:
2004
Document type:
Article
Affiliation country: